Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses
出版年份 2021 全文链接
标题
Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses
作者
关键词
-
出版物
Vaccines
Volume 9, Issue 5, Pages 463
出版商
MDPI AG
发表日期
2021-05-06
DOI
10.3390/vaccines9050463
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin‐derived mutant epitopes
- (2020) Allan Noé Domínguez‐Romero et al. IMMUNOLOGY
- Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs
- (2020) Jesús Zepeda-Cervantes et al. Frontiers in Immunology
- Turning the corner on therapeutic cancer vaccines
- (2019) Robert E. Hollingsworth et al. npj Vaccines
- Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
- (2019) Athanasios Mavratzas et al. Future Oncology
- Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
- (2018) Elizabeth K. Duperret et al. MOLECULAR THERAPY
- Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy
- (2018) Dapeng Zhou et al. MOLECULES
- Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
- (2018) Julie M. Collins et al. Expert Review of Vaccines
- Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
- (2018) Alessandra Lopes et al. Scientific Reports
- Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity
- (2017) Katrin Kramer et al. MOLECULAR THERAPY
- Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer
- (2017) Braeden Donaldson et al. Journal for ImmunoTherapy of Cancer
- Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
- (2016) MORENA ANTONILLI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
- (2016) Vani Lakshminarayanan et al. PLoS One
- Clinical management of breast cancer heterogeneity
- (2015) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
- (2015) O. A. Ali et al. Cancer Immunology Research
- Synthetic Multivalent Glycopeptide-Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor Cells
- (2014) Hui Cai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist
- (2014) Abu-Baker M. Abdel-Aal et al. CHEMBIOCHEM
- Induction of Antitumor Immunity by Dendritic Cells Loaded with Membrane-Translocating Mucin 1 Peptide Antigen
- (2014) Saho Kobukai et al. Translational Oncology
- Dendritic-Cell-Based Therapeutic Cancer Vaccines
- (2013) Karolina Palucka et al. IMMUNITY
- Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model
- (2013) Yu-Qian Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses
- (2012) Sara J. McKee et al. JOURNAL OF CONTROLLED RELEASE
- Antigen Incorporated In Virus-like Particles Is Delivered to Specific Dendritic Cell Subsets That Induce An Effective Antitumor Immune Response In Vivo
- (2012) Kunyu Li et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Construction and Characterization of Virus-Like Particles: A Review
- (2012) Andris Zeltins MOLECULAR BIOTECHNOLOGY
- Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines
- (2011) Barbara Romanowski Human vaccines & immunotherapeutics
- Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway
- (2011) Stephanie J Win et al. IMMUNOLOGY AND CELL BIOLOGY
- Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
- (2011) V. Lakshminarayanan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Survivin expression and targeting in breast cancer
- (2011) Kumkum Jha et al. SURGICAL ONCOLOGY-OXFORD
- MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells
- (2010) E. Lacunza et al. CANCER GENETICS AND CYTOGENETICS
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes
- (2009) Uta B. Hofmann et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
- (2008) Matthew Peacey et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search